Sponsor or institution
Clinical trials and research at Meng Chao Hepatobiliary Hospital of Fujian Medical University
As of November 12, 2026, Find a Trial lists 4 clinical trials run by Meng Chao Hepatobiliary Hospital of Fujian Medical University that are recruiting, in China. By phase: Phase 2 (2), Early Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Neoantigen Vaccine combined with Capecitabine for treating intrahepatic cholangiocarcinoma after surgery | Early Phase 1 | Fuzhou, Fujian | Recruiting | May 9, 2024 |
| Combining radiotherapy with camrelizumab and apatinib for liver cancer treatment | Phase 2 | Fuzhou, Fujian | Recruiting | Apr 5, 2024 |
| Combining cadonilimab and regorafenib for advanced liver cancer patients who didn't respond to previous treatment | Phase 2 | Fuzhou, Fujian | Recruiting | Feb 28, 2024 |
| Evaluating camrelizumab and apatinib mesylate for liver cancer treatment | — | Fuzhou, Fujian | Recruiting | Jun 8, 2022 |
All recruiting trials (4)
-
Neoantigen Vaccine combined with Capecitabine for treating intrahepatic cholangiocarcinoma after surgery
This study is testing if a new vaccine combined with a cancer drug can help patients with a specific type of liver cancer after surgery to reduce the chance of it coming back.
-
Combining radiotherapy with camrelizumab and apatinib for liver cancer treatment
This study is testing if a combination of radiation therapy with two medications can help shrink liver cancer tumors before surgery for patients whose cancer has spread to the portal vein.
-
Combining cadonilimab and regorafenib for advanced liver cancer patients who didn't respond to previous treatment
This study is testing if combining two drugs, cadonilimab and regorafenib, can help people with advanced liver cancer who didn't respond to earlier treatments.
-
Evaluating camrelizumab and apatinib mesylate for liver cancer treatment
This study is testing whether a combination of two drugs, camrelizumab and apatinib mesylate, can help people with liver cancer that can't be surgically removed feel better and improve their health.
Quick answers
How many clinical trials run by Meng Chao Hepatobiliary Hospital of Fujian Medical University are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.